Abstract
A variety of opportunistic pathogens have been reported to infect patients receiving tumor necrosis factor (TNF) antagonists for the treatment of autoimmune diseases. These pathogens are numerous, and include coccidioides, histoplasma, nontuberculous mycobacteria, Mycobacteria tuberculosis, and others of public health concern. Accordingly, TNF antagonists should be used with caution in patients at risk for tuberculosis, and screening for latent tuberculosis infection should be undertaken before anti-TNF therapy is initiated. Although screening and prevention efforts have decreased the risk of tuberculosis in this setting, optimal screening methods represent an area of evolving controversy. This article discusses the latest developments in screening methodologies for latent tuberculosis infection, as well as potential preventive and therapeutic considerations for opportunistic infections associated with anti-TNF agents and other biologic therapies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Furst, D. E. et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann. Rheum. Dis. 67 (Suppl. 3), iii2–iii25 (2008).
Winthrop, K. L. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat. Clin. Prat. Rheumatol. 2, 602–610 (2006).
Saag, K. G. et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 15, 762–784 (2008).
Tissot, F., Zanetti, G., Francioli, P., Zellweger, J. P. & Zysset, F. Influence of bacille Calmette–Guerin vaccination on size of tuberculin skin test reaction: to what size? Clin. Infect. Dis. 40, 211–217 (2005).
Pai, M., Riley, L. W. & Colford, J. M. Jr. Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect. Dis. 4, 761–776 (2004).
Beglinger, C. et al. Screening for tuberculosis infection before the initiation of an anti-TNF-alpha therapy. Swiss Med. Wkly 137, 620–622 (2007).
Ponce de Leon, D. et al. Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population. J. Rheumatol. 35, 776–781 (2008).
Matulis, G., Juni, P., Villiger, P. M. & Gadola, S. D. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases—performance of a mycobacterium tuberculosis antigen specific IFN-gamma assay. Ann. Rheum. Dis. 67, 84–90 (2008).
Vassilopoulos, D., Stamoulis, N., Hadziyannis, E. & Archimandritis, A. J. Usefulness of enzyme-linked immunospot assay (Elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment. J. Rheumatol. 35, 1271–1276 (2008).
Piana, F. et al. Use of a T-cell-based test for detection of tuberculosis infection among immunocompromised patients. Eur. Respir. J. 28, 31–34 (2006).
Lalvani, A. & Millington, K. A. Screening for tuberculosis infection prior to initiation of anti-TNF therapy. Autoimmun. Rev. 8, 147–152 (2008).
Hamdi, H. et al. Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists. Arthritis Res. Ther. 8, R114 (2006).
Winthrop, K. L., Siegel, J. N., Jereb, J., Taylor, Z. & Iademarco, M. F. Tuberculosis associated with therapy against tumor necrosis factor alpha. Arthritis Rheum. 52, 2968–2974
British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 60, 800–805 (2005).
Canadian Tuberculosis Committee. Updated recommendations on interferon gamma release assays for latent tuberculosis infection. Can. Commun. Dis. Rep. 34, 1–13 (2008).
[No authors listed] Targeted tuberculin testing and treatment of latent tuberculosis infection. Am. J. Respir. Crit. Care Med. 161, S221–S247 (2000).
CDC & American Thoracic Society. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection—United States, 2003. MMWR Morb. Mortal. Wkly Rep. 52, 735–739 (2003).
Carmona, L. et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum. 52, 1766–1772 (2005).
American Thoracic Society, CDC & Infectious Diseases Society of America. Treatment of tuberculosis. MMWR Reccom. Rep. 52, 1–77 (2003).
Winthrop, K. L., Yamashita, S., Beekman, S. E. & Polgreen, P. M. Mycobacterial and other serious infections in patients receiving anti-TNF and other newly approved biologic therapies; case-finding via the Emerging Infections Network. Clin. Infect. Dis. 46, 1738–1740 (2008).
Denis, B. et al. Long-term follow-up of patients with tuberculosis as a complication of tumour necrosis factor (TNF)-alpha antagonist therapy: safe re-initiation of TNF-alpha blockers after appropriate anti-tuberculous treatment. Clin. Microbiol. Infect. 14, 183–186 (2008).
Wheat, L. J. et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 45, 807–825 (2007).
McKinsey, D. S. et al. Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: randomized, placebo-controlled, double-blind study. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin. Infect. Dis. 28, 1049–1056 (1999).
Vail, G. M. et al. Incidence of histoplasmosis following allogeneic bone marrow transplant or solid organ transplant in a hyperendemic area. Transpl. Infect. Dis. 4, 148–151 (2002).
Valdivia, L. et al. Coccidioidomycosis as a common cause of community-acquired pneumonia. Emerg. Infect. Dis. 12, 958–962 (2006).
Chiller, T. M., Galgiani, J. N. & Stevens, D. A. Coccidioidomycosis. Infect. Dis. Clin. North Am. 17, 41–57, viii (2003).
Bergstrom, L. et al. Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists. Arthritis Rheum. 50, 1959–1966 (2004).
Wallis, R. S., Broder, M. S., Wong, J. Y., Hanson, M. E. & Beenhouwer, D. O. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin. Infect. Dis. 38, 1261–1265 (2004).
Acknowledgements
The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the US Centers for Disease Control and Prevention. K. L. Winthrop's work on this manuscript was funded by an Agency for Healthcare Research and Quality (AHRQ) grant (1K08HS017552-01).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
K. L. Winthrop declares he has received grant support from UCB, and has acted as a consultant for Genentech and Amgen. T. Chiller declares no competing interests.
Rights and permissions
About this article
Cite this article
Winthrop, K., Chiller, T. Preventing and treating biologic-associated opportunistic infections. Nat Rev Rheumatol 5, 405–410 (2009). https://doi.org/10.1038/nrrheum.2009.105
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2009.105
This article is cited by
-
The Association of Tuberculosis Mono-infection and Tuberculosis-Human Immunodeficiency Virus (TB-HIV) Co-infection in the Pathogenesis of Hypertensive Disorders of Pregnancy
Current Hypertension Reports (2020)
-
Update on the Epidemiology of Coccidioidomycosis
Current Fungal Infection Reports (2016)
-
Incidence of herpes zoster infections in juvenile idiopathic arthritis patients
Rheumatology International (2015)
-
“Serious skin & soft tissue infections in rheumatoid arthritis patients taking anti-tumor necrosis factor alpha drugs: a nested case–control study”
BMC Infectious Diseases (2013)
-
Bedfellows: mycobacteria and rheumatoid arthritis in the era of biologic therapy
Nature Reviews Rheumatology (2013)